Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Titans Of Pharma 2024

How do big pharma CEO compensation packages stack up against company performance? 

Read More

Featured Stories


AstraZeneca's Hopes Still High For Tozorakimab In COPD

The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients who had suffered moderate or severe exacerbations in the previous year.

Respiratory Clinical Trials Business Strategies

AstraZeneca/Daiichi Make Their Case For Dato-DXd In Non-Squamous Lung Cancer

Data at WCLC showed why the TROP2-targeting ADC datopotamab deruxtecan is most effective in non-squamous NSCLC in second or later lines as presented in overall survival data at the meeting.

Clinical Trials New Science Personalized Medicine

Merck & Co. and Daiichi’s Phase II ADC Hit Raises Expectations

Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.

Clinical Trials Companies Cancer

Asia Spotlight

Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine

Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview



Research & Development Vaccines

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Stock Watch: Regeneron Battles On Two Fronts

As it navigates product transition in ophthalmology against biosimilar and branded rivals, Regeneron seems to have a simpler challenge in another major therapeutic area.

Stock Watch Sales & Earnings

Pipeline Watch: Seven Approvals And 13 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Finance Watch: Summer Ends, But Fundraising Heats Up For ArsenalBio, Vaxcyte

ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.

Finance Watch Financing

Executives On The Move: Four New CEOs And Three New CFOs Among This Week's Changes

Recent moves in the industry include C-suite shuffle at Quantum Biopharma, Affimed and GH Research, plus Belite Bio and Dyne Therapeutics get new chief medical officers.

Leadership Executive Changes
Interviews

Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine

Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview

Research & Development Vaccines

Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse

“For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started to change with several positive readouts coming out of its immunology portfolio.

Leadership Business Strategies

AstraZeneca Believes Size Matters In Amyloidosis

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

Clinical Trials Cardiovascular

AstraZeneca Looks To Clinical Trial Innovations To Help Meet Oncology Ambitions

The company has created a single end-to-end cancer R&D organization to help it meet its ambitious oncology goals. Its chief medical officer Cristian Massacesi talks to Scrip about how developments in conducting clinical trials will help.

Companies Clinical Trials
See All
Graphics

Progress Or Hype? A Decade Of Cell Therapy In Japan

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Policy

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals M & A
See All
Recent Stories

Depemokimab’s Secondary Stumbles In Asthma

GSK’s ultra-long-acting biologic cuts asthma attacks, but misses on all the secondary endpoints in the twin SWIFT trials could limit its appeal.

Clinical Trials Respiratory

Evaxion Hopes To Impress Potential Partners At ESMO

The cash-strapped Danish biotech has got some positive news flow on its vaccines for gonorrhea and melanoma and believes that Phase II data on the latter in particular will attract attention at the major oncology conference kicking off in Barcelona this week.

Vaccines Cancer

Stock Watch: Regeneron Battles On Two Fronts

As it navigates product transition in ophthalmology against biosimilar and branded rivals, Regeneron seems to have a simpler challenge in another major therapeutic area.

Stock Watch Sales & Earnings

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Clinical Trials Research & Development

Terns’ Early Data May Position It Well In GLP-1 Obesity Race

In a multiple-ascending dose Phase I trial, Terns’ oral GLP-1 agonist showed 4.9% placebo-adjusted weight loss at 28 weeks, with no severe gastrointestinal side effects.

Clinical Trials Business Strategies

Relay To Take On AstraZeneca With RLY-2608 In PI3Kα-Mutated Breast Cancer

The firm is planning a head-to-head trial against AstraZeneca’s Truqap after RLY-2608 showed better safety and efficacy in a Phase I trial, including a four-month PFS benefit.

Business Strategies Clinical Trials

Immunovant’s Confidence In Graves’ Disease Builds

The Roivant-owned company announced positive Phase II data for batoclimab in Graves’ disease and plans to advance next-generation IMVT-1402 into Phase III.

Clinical Trials Rare Diseases

Pipeline Watch: Seven Approvals And 13 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine

Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview

Research & Development Vaccines

Akeso/Summit’s Bispecific Ivonescimab Bests Keytruda In 1L NSCLC

Ivonescimab has shown significant and "extremely commercially meaningful" improvements in progression-free survival versus Keytruda as a first-line therapy for lung cancer in a trial in China, potentially positioning it as a new chemo-free solution for all PD-L1-positive patients in this setting.

China Clinical Trials

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth.

Metabolic Disorders Cardiovascular

J&J’s Rybrevant/Lazcluze MARIPOSA Update Shows Greater Gains Over Tagrisso

Survival and other benefits with J&J’s EGFR/MET inhibitor Rybrevant plus EGFR inhibitor Lazcluze relative to AstraZeneca’s Tagrisso in first-line EGFR-mutant NSCLC continued to improve at 31.1 months.

Clinical Trials Personalized Medicine
UsernamePublicRestriction

Register